On the opposite side, IL-17 deficiency led to decreased tumor growth in B16 melanoma and MB49 bladder carcinoma models [72] and IL-17R−/− mice exhibited decreased tumor growth, when challenged with EL4 lymphoma, Tramp-C2 prostate cancer, or B16 melanoma tumor cells [73]. Here, IL17RA is linked to neoplasm.